DK1537078T3 - Indoler med anti-diabetisk aktivitet - Google Patents

Indoler med anti-diabetisk aktivitet

Info

Publication number
DK1537078T3
DK1537078T3 DK03791952.9T DK03791952T DK1537078T3 DK 1537078 T3 DK1537078 T3 DK 1537078T3 DK 03791952 T DK03791952 T DK 03791952T DK 1537078 T3 DK1537078 T3 DK 1537078T3
Authority
DK
Denmark
Prior art keywords
indoles
diabetic activity
diabetic
activity
Prior art date
Application number
DK03791952.9T
Other languages
English (en)
Inventor
Sheryl D Debenham
Regina M Black
John J Acton Iii
Kun Liu
Peter T Meinke
Harold B Wood
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK1537078T3 publication Critical patent/DK1537078T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
DK03791952.9T 2002-08-29 2003-08-27 Indoler med anti-diabetisk aktivitet DK1537078T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40674102P 2002-08-29 2002-08-29
US44067203P 2003-01-17 2003-01-17
PCT/US2003/027156 WO2004020409A1 (en) 2002-08-29 2003-08-27 Indoles having anti-diabetic activity

Publications (1)

Publication Number Publication Date
DK1537078T3 true DK1537078T3 (da) 2010-08-02

Family

ID=31981430

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03791952.9T DK1537078T3 (da) 2002-08-29 2003-08-27 Indoler med anti-diabetisk aktivitet

Country Status (23)

Country Link
US (2) US7186746B2 (da)
JP (1) JP4377815B2 (da)
KR (1) KR20050057074A (da)
CN (1) CN100457730C (da)
AU (1) AU2003265681A1 (da)
BR (1) BR0313825A (da)
CA (1) CA2495943C (da)
DE (1) DE60332125D1 (da)
DK (1) DK1537078T3 (da)
EC (1) ECSP055632A (da)
ES (1) ES2342596T3 (da)
HK (1) HK1083836A1 (da)
HR (1) HRP20050181A2 (da)
IL (1) IL166764A0 (da)
IS (1) IS7680A (da)
MA (1) MA27396A1 (da)
MX (1) MXPA05002303A (da)
NO (1) NO20051546L (da)
NZ (1) NZ538031A (da)
PL (1) PL375302A1 (da)
PT (1) PT1537078E (da)
RU (1) RU2328483C2 (da)
WO (2) WO2004020408A1 (da)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4340232B2 (ja) * 2002-08-29 2009-10-07 メルク エンド カムパニー インコーポレーテッド 抗糖尿病活性を有するインドール類
BR0313825A (pt) * 2002-08-29 2005-07-12 Merck & Co Inc Composto, composição farmacêutica, método para tratar de diabete mellitus tipo 2 em um mamìfero, e, uso de composto
EP1599468B1 (en) 2003-01-14 2007-10-03 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
CN1794989A (zh) * 2003-04-14 2006-06-28 药物研发有限责任公司 用于治疗糖尿病的n－(((((1,3－噻唑－2－基)氨基)羰基)苯基)磺酰基)苯丙氨酸衍生物及相关化合物
EA200501710A1 (ru) 2003-04-30 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые карбоновые кислоты
NZ544200A (en) 2003-07-14 2009-07-31 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7491744B2 (en) 2004-04-26 2009-02-17 Vanderbilt University Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
EP1758856A2 (en) * 2004-05-04 2007-03-07 Novo Nordisk A/S Indole derivatives for the treatment of obesity
US20080076810A1 (en) * 2004-05-28 2008-03-27 Weiguo Lui Benzoureas Having Anti-Diabetic Activity
WO2005115382A1 (en) * 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for medicinal uses
EP1765329A2 (en) * 2004-07-02 2007-03-28 Merck & Co., Inc. Indoles having anti-diabetic activity
MX2007001259A (es) 2004-07-30 2007-10-08 Salvat Lab Sa Derivados de tirosina como moduladores de receptores activadores proliferadores de peroxisomas-gamma.
WO2006060535A2 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
JPWO2006075638A1 (ja) * 2005-01-14 2008-06-12 大日本住友製薬株式会社 新規ヘテロアリール誘導体
EP1841735B1 (en) * 2005-01-19 2011-03-09 Biolipox AB Indoles useful in the treatment of inflammation
EP1854779A4 (en) * 2005-03-01 2010-07-21 Kowa Co OPTICALLY ACTIVE, PPAR-ACTIVATING COMPOSITE INTERMEDIATE PRODUCT AND MANUFACTURING METHOD THEREFOR
CN102584754B (zh) 2005-03-04 2016-02-03 默沙东公司 具有抗糖尿病活性的稠合芳香化合物
CA2599710A1 (en) * 2005-03-10 2006-09-21 Merck & Co., Inc. Novel crystalline forms of antidiabetic compounds
MX2008003202A (es) * 2005-09-16 2008-03-25 Serenex Inc Derivados de carbazol.
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
WO2007149456A2 (en) 2006-06-19 2007-12-27 Vanderbilt University Methods and compositions for diagnostic and therapeutic targeting of cox-2
TW200821284A (en) * 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
NZ600947A (en) 2007-01-26 2012-12-21 Kaneq Pharma Inc Fused Aromatic Difluoromethanephosphonates as Protein Tyrosine Phosphatase 1B (PTP-1B) Inhibitors
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
JP2010526807A (ja) 2007-05-07 2010-08-05 メルク・シャープ・エンド・ドーム・コーポレイション 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法
RU2361581C2 (ru) * 2007-09-14 2009-07-20 Закрытое Акционерное Общество "Мастерклон" Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
WO2010068311A1 (en) 2008-05-23 2010-06-17 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein inhibitor
WO2010001869A1 (ja) * 2008-06-30 2010-01-07 武田薬品工業株式会社 ４置換ベンゼン化合物およびその用途
TWI614024B (zh) * 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
EP2389226B1 (en) 2009-01-23 2013-11-20 Merck Sharp & Dohme Corp. Bridged and fused heterocyclic antidiabetic compounds
AU2010206789A1 (en) 2009-01-23 2011-07-28 Merck Sharp & Dohme Corp. Bridged and fused antidiabetic compounds
TW201040186A (en) 2009-02-05 2010-11-16 Schering Corp Phthalazine-containing antidiabetic compounds
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US8552022B2 (en) 2009-08-13 2013-10-08 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
JP5734981B2 (ja) 2009-09-02 2015-06-17 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノテトラヒドロピラン
US8754099B2 (en) 2010-01-15 2014-06-17 Merck Sharp & Dohme Corp Oxadiazole beta carboline derivatives as antidiabetic compounds
CA2787785C (en) 2010-01-28 2018-03-06 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
EP2538783B1 (en) 2010-02-22 2016-06-01 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
JP2013100235A (ja) * 2010-03-08 2013-05-23 Dainippon Sumitomo Pharma Co Ltd 新規インドール誘導体
US8785634B2 (en) 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
WO2011143057A1 (en) 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
WO2011146358A1 (en) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2012024183A1 (en) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
EP2606031B1 (en) 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US9108920B2 (en) 2010-10-29 2015-08-18 Merck Sharp & Dohme Corp. Diazeniumdiolate heterocyclic derivatives
CA2824344A1 (en) 2011-01-20 2012-07-26 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
CA2831334A1 (en) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012139495A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2012151114A1 (en) 2011-05-02 2012-11-08 Merck Sharp & Dohme Corp. Diazeniumdiolate cyclohexyl derivatives
EP2707101B1 (en) * 2011-05-12 2019-02-13 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2012166415A1 (en) 2011-05-27 2012-12-06 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
AU2012264651A1 (en) 2011-06-02 2013-12-12 Intervet International B.V. Imidazole derivatives
JP2014517036A (ja) 2011-06-16 2014-07-17 メルク・シャープ・アンド・ドーム・コーポレーション 置換シクロプロピル化合物、そのような化合物を含有する組成物および治療方法
WO2013048916A1 (en) 2011-09-30 2013-04-04 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
US9505730B2 (en) 2011-10-13 2016-11-29 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
EP3078374B1 (en) 2011-10-17 2019-06-19 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
WO2013068328A1 (en) 2011-11-07 2013-05-16 Intervet International B.V. Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
WO2013068439A1 (en) 2011-11-09 2013-05-16 Intervet International B.V. 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
US9018224B2 (en) 2011-11-15 2015-04-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
US9073930B2 (en) 2012-02-17 2015-07-07 Merck Sharp & Dohme Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20150064111A1 (en) * 2012-04-03 2015-03-05 Aposense Ltd. Novel targeting agents for diagnostic and therapeutic indications
IN2014DN09640A (da) 2012-04-16 2015-07-31 Kaneq Pharma Inc
WO2014018350A1 (en) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-iv inhibitors
WO2014099578A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment
WO2014099836A1 (en) 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. Spirocyclic cetp inhibitors
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
EP3046905A4 (en) 2013-09-17 2017-03-22 Pharmakea Inc. Vinyl autotaxin inhibitor compounds
WO2015042052A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
PL3071561T3 (pl) 2013-11-22 2021-11-08 Sabre Therapeutics Llc Związki inhibitora autotaksyny
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
EP3097101B1 (en) 2014-01-24 2020-12-23 Merck Sharp & Dohme Corp. Isoquinoline derivatives as mgat2 inhibitors
ES2747989T3 (es) * 2014-05-20 2020-03-12 Raqualia Pharma Inc Sal de derivado de benzisoxazol
EP3174537B1 (en) 2014-07-29 2021-06-23 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
WO2016022742A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
MA55068A (fr) 2014-10-24 2022-01-05 Merck Sharp & Dohme Co-agonistes des récepteurs du glucagon et du glp-1
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之***并吡基衍生物
MX2021011472A (es) 2015-01-06 2022-08-17 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
WO2016191334A1 (en) 2015-05-27 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
US10632104B2 (en) 2015-05-27 2020-04-28 Sabre Therapeutics Llc Autotaxin inhibitors and uses thereof
US10213429B2 (en) 2015-05-28 2019-02-26 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
US20180230166A1 (en) 2015-07-13 2018-08-16 Merck Sharp & Dohme Corp. Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
US10800826B2 (en) 2015-10-05 2020-10-13 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
BR112018006866B1 (pt) * 2015-10-07 2023-11-21 Mitobridge, Inc. Compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
WO2017095724A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
WO2017095725A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
CN107286158A (zh) * 2016-03-30 2017-10-24 中国科学院上海药物研究所 苯基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用
EP3442948B1 (en) 2016-04-13 2020-12-16 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
WO2017201683A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
US10414774B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease
EP3496715B1 (en) 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
EP3515891B1 (en) 2016-09-20 2023-03-08 Merck Sharp & Dohme LLC Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as pcsk9 allosteric binders
CN109963561A (zh) 2016-11-18 2019-07-02 默沙东公司 可用作二酰基甘油酯o-酰基转移酶2的抑制剂的吲哚衍生物
WO2018107415A1 (en) 2016-12-15 2018-06-21 Merck Sharp & Dohme Corp. Hydroxy isoxazole compounds useful as gpr120 agonists
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
US20220177465A1 (en) 2019-04-04 2022-06-09 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
WO2020236688A1 (en) 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
WO2020236690A1 (en) 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
WO2021041770A1 (en) 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
EP3842060A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors
EP3842449A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors
WO2021236401A1 (en) 2020-05-18 2021-11-25 Merck Sharp & Dohme Corp. Novel diacylglyceride o-acyltransferase 2 inhibitors
IL310851A (en) 2021-08-19 2024-04-01 Merck Sharp & Dohme Llc Compounds for the treatment of diseases associated with PCSK9 activity
TW202404574A (zh) 2022-06-15 2024-02-01 美商默沙東有限責任公司 用於捕捉介白素-1 β之環狀肽

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686481A (en) * 1993-12-21 1997-11-11 Smithkline Beecham Corporation Endothelin receptor antagonists
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
WO1998008818A1 (en) 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
KR20010041344A (ko) 1998-02-25 2001-05-15 브루스 엠. 에이센, 토마스 제이 데스로저 포스포리파제 효소의 억제제
KR20010041346A (ko) 1998-02-25 2001-05-15 브루스 엠. 에이센, 토마스 제이 데스로저 포스포리파제 ａ2 억제제
CN1299347A (zh) 1998-02-25 2001-06-13 遗传研究所有限公司 磷脂酶抑制剂
US6214991B1 (en) * 1998-03-31 2001-04-10 The Institute For Pharmaceutical Discovery, Inc. Substituted indolealkanoic acids
GB2362173B (en) * 1998-11-10 2003-05-28 Baker Hughes Inc Self-controlled directional drilling systems and methods
EE200100323A (et) 1998-12-18 2002-08-15 Axys Pharmaceuticals, Inc. (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena
JP2003525217A (ja) * 1999-10-22 2003-08-26 メルク エンド カムパニー インコーポレーテッド 肥満治療用薬剤
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
HUP0302477A2 (hu) 2000-10-10 2003-12-29 Smithkline Beecham Corp. Szubsztituált indolszármazékok, ezeket tartalmazó gyógyszerkészítmények és ezek alkalmazása PPAR-gamma kötő szerként
US6706751B2 (en) * 2000-12-21 2004-03-16 Hoffman-La Roche Inc. Dihydroindole and tetrahydroquinoline derivatives
US7153852B2 (en) 2001-09-07 2006-12-26 Ono Pharmaceutical Co., Ltd. Indole compounds, process for producing the same and drugs containing the same as the active ingredient
GB0205165D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7125906B2 (en) * 2002-04-03 2006-10-24 Astrazeneca Ab Indole derivatives having anti-angiogenetic activity
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
BR0313825A (pt) * 2002-08-29 2005-07-12 Merck & Co Inc Composto, composição farmacêutica, método para tratar de diabete mellitus tipo 2 em um mamìfero, e, uso de composto
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
AR048282A1 (es) * 2003-08-01 2006-04-19 Janssen Pharmaceutica Nv Indol- o - glucosidos sustituidos

Also Published As

Publication number Publication date
WO2004020409A1 (en) 2004-03-11
NO20051546L (no) 2005-05-24
CN1678578A (zh) 2005-10-05
HK1083836A1 (en) 2006-07-14
RU2328483C2 (ru) 2008-07-10
AU2003265681A1 (en) 2004-03-19
US20050277685A1 (en) 2005-12-15
CN100457730C (zh) 2009-02-04
IL166764A0 (en) 2006-01-15
PT1537078E (pt) 2010-06-18
MXPA05002303A (es) 2005-06-08
DE60332125D1 (de) 2010-05-27
ES2342596T3 (es) 2010-07-09
WO2004020408A1 (en) 2004-03-11
PL375302A1 (en) 2005-11-28
US20070161689A1 (en) 2007-07-12
IS7680A (is) 2005-01-31
US7345085B2 (en) 2008-03-18
JP2006500384A (ja) 2006-01-05
MA27396A1 (fr) 2005-06-01
RU2005108668A (ru) 2005-08-27
JP4377815B2 (ja) 2009-12-02
US7186746B2 (en) 2007-03-06
HRP20050181A2 (en) 2006-03-31
BR0313825A (pt) 2005-07-12
KR20050057074A (ko) 2005-06-16
CA2495943A1 (en) 2004-03-11
ECSP055632A (es) 2005-04-18
CA2495943C (en) 2009-07-21
NZ538031A (en) 2007-10-26

Similar Documents

Publication Publication Date Title
DK1537078T3 (da) Indoler med anti-diabetisk aktivitet
DE60336314D1 (de) Substituierte indole
EP1546142A4 (en) INDOLES HAVING ANTIDIABETIC EFFECT
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
DE60330372D1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
ATE438644T1 (de) Chinazolinderivate
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
DE60312848D1 (de) Verbindungsanschluss
DK1513861T3 (da) Etonogestrelestere
DE60307512D1 (de) 3h-chinazoline -4-on derivaten
DE50309213D1 (de) Befestigungsanordnung
ATE423771T1 (de) Tetrahydrochinolinderivate
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
IS7906A (is) Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls
ES1051167Y (es) Sofa perfeccionado
ATE405560T1 (de) Indolderivaten
NO20043433L (no) Fremgangsmate
SI1537078T1 (sl) Indoli, ki delujejo proti sladkorni bolezni
FR2846209B1 (fr) Structure de couchage
ES1052487Y (es) Dintel perfeccionado
ES1051542Y (es) Recipiente-contenedor perfeccionado
ITFI20020242A1 (it) Orditoio perfezionato